NAPLEX • Medication Use Process

Sharps Handling

Safe sharps management protects healthcare workers, patients, and communities from needlestick injuries and bloodborne pathogen transmission.

NAPLEX emblem with a medicine bottle, dosage calculator, and verification checks.
Inside this lesson 10 sections 5 questions 5 figures

SECTION 1

Historical Context & Motivation

The practice of safe sharps handling in healthcare settings evolved from decades of occupational injuries and the growing understanding of bloodborne pathogen transmission. Before formalized guidelines existed, healthcare workers routinely recapped needles by hand, disposed of sharps in regular waste bins, and experienced needlestick injuries at alarming rates. The emergence of HIV/AIDS in the 1980s catalyzed a fundamental transformation in how the healthcare industry approached sharps safety, culminating in sweeping federal regulations that continue to shape pharmacy and clinical practice today. Understanding the historical trajectory of sharps safety regulations is essential for pharmacists, who serve as frontline practitioners responsible for safe medication preparation, administration, and disposal across diverse healthcare environments.

1987 • Universal Precautions Concept

The CDC introduced Universal Precautions in response to the HIV/AIDS epidemic, recommending that all human blood and certain body fluids be treated as potentially infectious. This paradigm shift moved healthcare away from risk-based assessments toward consistent protective protocols.

1991 • OSHA Bloodborne Pathogens Standard

The Occupational Safety and Health Administration (OSHA) enacted 29 CFR 1910.1030, the Bloodborne Pathogens Standard, mandating employer-developed Exposure Control Plans, engineering controls, and employee training for sharps safety.

2000 • Needlestick Safety and Prevention Act

Congress passed the Needlestick Safety and Prevention Act, requiring employers to evaluate and implement safer needle devices, maintain a sharps injury log, and involve frontline workers in device selection.

2001 • Revised OSHA Standard

OSHA updated the Bloodborne Pathogens Standard to incorporate the Needlestick Safety Act requirements, including mandated use of safety-engineered sharps devices (SESDs) and annual review of Exposure Control Plans.

2012–Present • USP and State Pharmacy Board Expansions

USP chapters <797> and <800> incorporated sharps safety into sterile compounding and hazardous drug handling standards, while state boards of pharmacy adopted facility-specific sharps management requirements for retail and institutional pharmacies.

Despite these legislative advances, the CDC estimates that approximately 385,000 needlestick and other sharps-related injuries occur annually among hospital-based healthcare workers in the United States. Pharmacists preparing injectable medications, reconstituting hazardous drugs, or administering immunizations must understand how proper sharps handling reduces the risk of transmitting hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV). This section of the NAPLEX evaluates your ability to apply these regulations, select appropriate engineering controls, and educate patients and staff on safe disposal practices.

SECTION 2

Core Principles & Definitions

Effective sharps handling rests on a hierarchy of controls that begins with engineering solutions and extends through work practice controls, personal protective equipment, and proper waste management. The pharmacist's role spans the entire medication use process—from drawing up injectable medications in a sterile compounding environment to counseling patients on safe home disposal of insulin syringes. A firm grasp of core definitions is the foundation for mastering the regulatory and practical dimensions tested on the NAPLEX.

1

Sharps — Definition & Scope

Any device or object capable of puncturing or cutting the skin, including hypodermic needles, scalpels, lancets, broken glass ampules, and contaminated broken vials. Auto-injector pens with exposed needles and reconstitution devices with attached needles also qualify as sharps.
2

Engineering Controls

Physical devices that isolate or remove the sharps hazard from the worker, such as safety-engineered sharps devices (SESDs), retractable needles, needleless IV connectors, and FDA-cleared sharps containers. Engineering controls are the first and most effective tier in the hierarchy of controls.
3

Work Practice Controls

Behavioral procedures that reduce the likelihood of exposure, including the prohibition of two-handed needle recapping, the one-handed scoop technique when recapping is unavoidable, and passing sharps in a neutral zone (e.g., a tray or basin) rather than hand-to-hand.
4

Sharps Disposal Containers

Puncture-resistant, leak-proof, closable, and labeled (biohazard symbol or red color) containers meeting OSHA and state requirements. Containers must be accessible at the point of use and replaced when three-quarters full to prevent overfilling-related injuries.
5

Post-Exposure Prophylaxis (PEP)

The pharmacist must understand the urgency of PEP protocols following a sharps injury: immediate wound care, employer notification, baseline serologic testing, and prophylactic antiretroviral or immunoglobulin therapy initiated ideally within 1–2 hours of exposure.
✦

KEY TAKEAWAY

Think of the sharps safety hierarchy like the layers of a fortress. The engineering controls are the outer walls—they physically prevent the hazard from reaching you. Work practice controls are the guards patrolling inside—they rely on trained human behavior. PPE is the personal armor worn as a last line of defense. You always build from the outside in: engineer the hazard away first, then layer behavioral and personal protections.

SECTION 3

Visual Explanation — Hierarchy of Sharps Safety Controls

Hierarchy of Sharps Safety ControlsMost effective at top → Least effective at bottomELIMINATIONNeedleless systems, oral alternativesENGINEERING CONTROLSSESDs, retractable needles, sharps containersNeedleless IV connectors, blunt-tip cannulasWORK PRACTICE CONTROLSNo two-handed recapping, one-handed scoop, neutral zone passingImmediate disposal at point of usePPE (PERSONAL PROTECTIVE EQUIPMENT)Gloves, gowns, eye protection — last line of defenseMOSTEFFECTIVELEASTEFFECTIVEOSHA 29 CFR 1910.1030 — Hierarchy of Controls for Sharps Safety
This pyramid illustrates the hierarchy of sharps safety controls. Elimination strategies (top) are most effective, while PPE (bottom) represents the last line of defense. Pharmacists should prioritize engineering controls—such as safety-engineered sharps devices and needleless connectors—before relying on behavioral or personal protective strategies.

The pyramid above captures the core regulatory philosophy embedded in the OSHA Bloodborne Pathogens Standard: eliminate the hazard first whenever clinically feasible. When elimination is not possible—as is often the case with parenteral medications, immunizations, and insulin therapy—the next priority is engineering the hazard away through safety devices. Only after these two tiers have been addressed should the organization layer work practice controls and PPE. For the NAPLEX, it is critical to recognize that the failure to use available engineering controls (e.g., continuing to use conventional needles when SESDs exist) represents a violation of OSHA requirements and exposes healthcare workers to preventable risk.

SECTION 4

Mechanism — The Sharps Lifecycle in Pharmacy Practice

Understanding sharps handling requires tracing the complete lifecycle of a sharp from the moment it enters the pharmacy workflow until its final destruction. Each transition point presents specific hazards, and the pharmacist must apply the appropriate controls at each stage. This lifecycle model integrates the regulatory mandates of OSHA, the practical standards of USP, and the clinical realities of medication preparation and administration.

Stage 1 — Selection & Procurement

The sharps lifecycle begins with device selection. Under the revised OSHA standard, employers must evaluate and implement commercially available safety-engineered sharps devices unless the employer can demonstrate that such devices are not available, would compromise patient care, or are not more effective. Frontline healthcare workers, including pharmacists, must be solicited for input during the annual evaluation process. Device selection considerations include needle gauge and length requirements, activation mechanism reliability, compatibility with existing drug delivery systems, and cost-effectiveness analyses.

Stage 2 — Use & Activation

During the medication preparation and administration phase, the pharmacist must activate safety mechanisms at the earliest appropriate point. For retractable syringes, the spring-loaded barrel retracts the needle immediately after injection. For hinged-cap devices, the operator pushes the shield forward over the needle using one hand immediately after withdrawal. The one-handed scoop technique is employed when temporary recapping is clinically necessary—for example, when a pharmacist draws up a medication in a sterile compounding suite and must transport it to the patient care area. The cap is placed on a flat surface, the needle is slid into the cap using one hand, and the cap is secured against the surface. Two-handed recapping is strictly prohibited by OSHA regulations.

Stage 3 — Immediate Disposal

The used sharp must be placed into a compliant sharps container immediately at the point of use without passing through intermediate locations. OSHA specifies that sharps containers must be closable, puncture-resistant, leak-proof on sides and bottom, and labeled or color-coded red. Containers should be replaced when they reach the three-quarters fill line—never forced shut or overfilled. In pharmacy immunization areas, mobile sharps containers must be within arm's reach of the administering pharmacist. Needles must never be bent, broken, or sheared from syringes prior to disposal.

Stage 4 — Transport, Treatment & Final Disposal

Sealed sharps containers are classified as regulated medical waste (RMW) and must be transported according to DOT and state environmental regulations. Treatment methods include autoclaving, incineration, microwave disinfection, and chemical treatment. Pharmacies that generate sharps waste must contract with licensed medical waste haulers or use mail-back sharps disposal programs for community pharmacy settings. Patient-generated sharps (e.g., insulin syringes, lancets) fall under state-specific household hazardous waste regulations, and pharmacists play a critical counseling role in educating patients about FDA-cleared home sharps containers and local take-back programs.

SECTION 5

Classification of Sharps & Safety Devices

Sharps Classification & Safety Device TypesALL SHARPSHOLLOW-BORE NEEDLESSOLID SHARPSGLASS SHARPS• Hypodermic needles• IV catheter stylets• Blood collection needles• Spinal/epidural needlesHIGHEST RISK(blood retained in bore)• Suture needles• Scalpel blades• Lancets• Razor bladesMODERATE RISK(surface contamination only)• Broken ampules• Cracked vials• Glass slides• PipettesVARIABLE RISK(depends on contents)Safety-Engineered Sharps Devices (SESDs)RETRACTABLESpring-loaded needleretracts into barrelafter injectionPASSIVE ✓SHIELDEDHinged cap slidesover needle withone-handed activationACTIVE ⚡BLUNTINGBlunt inner cannulaextends past sharptip after usePASSIVE ✓NEEDLELESSLuer-lock or valveconnectors eliminateneedle entirelyELIMINATION ★
This classification tree shows three categories of sharps—hollow-bore needles (highest risk due to blood retention), solid sharps, and glass sharps—along with four categories of safety-engineered sharps devices. Passive devices (retractable, blunting) are preferred over active devices because they do not depend on user compliance for activation.

The distinction between passive and active safety devices carries significant implications for device selection. Passive devices—those that activate automatically without requiring a conscious action by the user—are generally preferred because they maintain protection even when the operator is fatigued, distracted, or rushing. Active devices require the user to manually engage the safety mechanism, which introduces the possibility of noncompliance. For the NAPLEX, remember that needleless systems represent true elimination and are the gold standard wherever clinically appropriate, particularly for IV access, medication port connections, and reconstitution procedures.

Sharps TypeCommon Pharmacy ExamplesRequired Disposal ContainerKey Regulation
Hypodermic needlesImmunization needles, reconstitution needles, insulin syringesFDA-cleared sharps container (red/biohazard labeled)OSHA 29 CFR 1910.1030
LancetsBlood glucose monitoring, point-of-care testingSharps container; FDA-cleared home container for patientsOSHA; state-specific HHW rules
Broken ampulesInjectable drug preparation, sterile compoundingSharps container (not regular glass waste)USP <797>; OSHA
Auto-injector pensEpinephrine (EpiPen), insulin pens with exposed needlesSharps container; community disposal programsFDA guidance; state pharmacy board rules
Contaminated broken vialsHazardous drug vials (USP <800>), cytotoxic agentsSharps container rated for hazardous waste; dual containmentUSP <800>; EPA RCRA (if listed)

Common sharps encountered in pharmacy practice with disposal requirements

SECTION 6

Worked Example — Sharps Injury Response Protocol

The following scenario demonstrates the step-by-step protocol a pharmacist should follow after a sharps injury occurs. This integrates OSHA requirements, CDC post-exposure prophylaxis (PEP) guidelines, and institutional policy obligations—all of which are testable domains on the NAPLEX.

Scenario: Needlestick Injury During Immunization Administration

  1. 1

    Step 1 — Immediate Wound Care

    A pharmacist administering an influenza vaccine accidentally sustains a needlestick injury from the used needle while activating the safety shield. The pharmacist should immediately wash the puncture site thoroughly with soap and running water for at least 20 seconds. If the exposure involved the eyes, nose, or mouth, the affected area should be flushed with clean water, saline, or sterile irrigant. Antiseptics (e.g., chlorhexidine) may be applied but are not a substitute for thorough washing. Do NOT squeeze the wound to force blood out, as this may increase tissue damage and pathogen exposure.
    Immediate action: Wash site with soap and water for ≥ 20 seconds.
  2. 2

    Step 2 — Report to Supervisor & Document

    The pharmacist must notify the pharmacy manager or designated supervisor immediately and complete an OSHA Sharps Injury Log entry. This log must include the type and brand of device involved, the department or work area, and an explanation of how the injury occurred. The injured worker's identity must remain confidential on the log. An incident report should also be filed per institutional policy, and the employer must offer a confidential medical evaluation at no cost to the employee.
    Document: Complete OSHA Sharps Injury Log and institutional incident report.
  3. 3

    Step 3 — Identify Source Patient Status

    In this immunization scenario, the source is a known patient. The employer should request (with the patient's consent) that the source patient be tested for HBV, HCV, and HIV serology. If the source patient's status is unknown or the patient refuses testing, the exposed worker should be treated as if the source is potentially positive. Baseline serology (HBsAg, anti-HBs, anti-HCV, HIV antibody/antigen) is drawn from the injured pharmacist at this time.
    Test source patient (with consent) and draw baseline serology on exposed worker.
  4. 4

    Step 4 — Evaluate Need for Post-Exposure Prophylaxis (PEP)

    For HIV PEP, the CDC recommends initiation ideally within 1–2 hours of exposure and no later than 72 hours. The preferred regimen typically includes a three-drug antiretroviral combination (e.g., tenofovir DF/emtricitabine plus raltegravir or dolutegravir) for 28 days. For HBV exposure in an unvaccinated or non-responding worker, hepatitis B immune globulin (HBIG) and HBV vaccine series should be initiated. HCV has no approved PEP; follow-up serology at 4–6 months is the standard approach. The pharmacist's documented immunization history (e.g., confirmed anti-HBs ≥ 10 mIU/mL) determines HBV PEP necessity.
    Initiate HIV PEP within 1–2 hours; assess HBV immunity; no PEP exists for HCV.
  5. 5

    Step 5 — Follow-Up and Root Cause Analysis

    The injured pharmacist undergoes follow-up serologic testing at 6 weeks, 12 weeks, and 6 months post-exposure (or per institutional protocol). Simultaneously, the employer must conduct a root cause analysis to determine whether the injury was related to device design failure, inadequate training, environmental factors (e.g., poor lighting, cluttered workspace), or human error. Findings should inform the annual Exposure Control Plan review, potentially leading to device changes, retraining, or workflow modifications.
    Follow-up serology at 6, 12, and 24 weeks; conduct root cause analysis to prevent recurrence.

SECTION 7

Regulatory Compliance — Comparing Standards

Pharmacists must navigate overlapping federal, state, and professional standards governing sharps handling. The following comparison highlights the key regulatory frameworks, their scope, and their specific requirements relevant to pharmacy practice. Understanding where these standards converge and diverge is essential for maintaining compliant operations across community, hospital, and compounding pharmacy settings.

Regulatory StandardScope & ApplicabilityKey Sharps Requirements
OSHA BBP Standard (29 CFR 1910.1030)All employers with workers who have reasonably anticipated occupational exposure to blood or OPIMExposure Control Plan; SESDs; sharps containers at point of use; sharps injury log; annual plan review; no two-handed recapping; free HBV vaccination
Needlestick Safety and Prevention Act (2000)Amendment to OSHA BBP Standard; applies to same workforceMandatory evaluation and adoption of safer needle devices; frontline worker involvement in device selection; detailed sharps injury log with device type and brand
USP <797>Facilities performing sterile compounding (pharmacies, hospitals, outsourcing facilities)Broken ampule glass disposal in sharps containers; proper needle/syringe handling inside cleanroom; filter needle/straw requirements for ampule withdrawals to prevent glass particulate contamination
USP <800>Facilities handling hazardous drugs (HD) throughout the medication use processClosed-system transfer devices (CSTDs) for HDs; chemotherapy-rated sharps containers; double containment; deactivation/decontamination of contaminated sharps waste before transport
EPA / RCRA / State HHW RulesPatient-generated sharps waste; community sharps disposal programsFDA-cleared home sharps containers; mail-back programs; community collection sites; pharmacist counseling on proper home disposal; prohibition of sharps in household trash (varies by state)

Comparison of federal and professional standards governing sharps handling in pharmacy

⚖️

KEY TAKEAWAY

Think of regulatory compliance like a Venn diagram where OSHA sets the floor (minimum requirements all employers must meet), while USP chapters and state boards layer additional, often stricter, requirements for specific practice settings. A hospital pharmacy performing hazardous drug sterile compounding must comply simultaneously with OSHA, USP <797>, and USP <800>—meaning they apply the most stringent requirement from each standard. When in doubt on the NAPLEX, default to the strictest applicable standard.

SECTION 8

Connections to Advanced Practice — Hazardous Drug Handling & USP <800>

Sharps handling takes on additional complexity when hazardous drugs (HDs) are involved. Under USP <800>, all personnel who handle HDs—from receiving through disposal—must follow enhanced protective protocols that extend well beyond standard OSHA requirements. A contaminated sharp that has contacted a cytotoxic agent (e.g., cyclophosphamide, methotrexate) poses both a bloodborne pathogen risk and a chemical exposure risk, requiring dual-hazard containment strategies.

FeatureStandard Sharps HandlingHazardous Drug Sharps Handling (USP <800>)
Transfer devicesStandard needles or SESDsClosed-system transfer devices (CSTDs) required for administration of antineoplastic HDs; recommended for compounding
Container typeStandard red biohazard sharps containerChemotherapy-rated sharps container (yellow with CHEMO label); trace-contaminated waste pathway
PPE requirementsGloves (single pair); gown if splash riskDouble chemotherapy-rated gloves, impervious gown, eye/face protection; respiratory protection per assessment of risk
Spill managementStandard spill kit; absorbent materialsHD spill kit required; deactivation/decontamination/cleaning protocol; contaminated sharps treated as hazardous waste
Final disposalRegulated medical waste stream (autoclave or incineration)RCRA-listed HDs require hazardous waste disposal per EPA regulations; trace-contaminated waste may follow state-specific rules

Standard vs. hazardous drug sharps handling requirements

As pharmacy practice continues to evolve—with expanding immunization authority, point-of-care testing, and increasing use of specialty biologics requiring subcutaneous injection—pharmacists will encounter sharps handling challenges in increasingly diverse settings. The integration of closed-system transfer devices, smart sharps containers with RFID-based fill monitoring, and automated disposal tracking systems represents the frontier of sharps safety technology. For NAPLEX preparation, focus on the regulatory hierarchy (OSHA → Needlestick Act → USP → state boards), the post-exposure protocol, and the principles of device selection—these form the testable core of sharps handling competency.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A pharmacy technician asks why retractable safety needles are preferred over shielded (hinged-cap) safety needles in many institutional formularies. Which of the following best explains the preference for retractable devices?
Show answer
Retractable needles are classified as passive safety-engineered sharps devices, meaning the safety mechanism activates automatically (spring-loaded retraction) without requiring a deliberate action by the user. Shielded (hinged-cap) devices are active devices that require the operator to manually push the guard over the needle. Passive devices are preferred because they remove the possibility of noncompliance—the safety mechanism engages regardless of user fatigue, distraction, or time pressure. This distinction directly aligns with OSHA's emphasis on engineering controls as the highest-priority intervention below elimination.

Question 2: BASIC CALCULATION

A community pharmacy immunization clinic uses 1.5-quart sharps containers that should be replaced at the three-quarters fill line. If the pharmacy administers an average of 40 immunizations per day and each used syringe-needle unit occupies approximately 12 mL of container volume, how many days will one sharps container last before needing replacement? (1 quart ≈ 946 mL)
Show answer
First, calculate the total container volume: 1.5 quarts × 946 mL/quart = 1,419 mL. The usable volume at three-quarters capacity is 1,419 × 0.75 = 1,064.25 mL. Daily sharps volume is 40 immunizations × 12 mL = 480 mL per day. Dividing: 1,064.25 ÷ 480 ≈ 2.22 days. Therefore, the container should be replaced approximately every 2 days during active immunization campaigns. The pharmacy should never wait until a container appears full—the three-quarters rule exists to prevent overfilling injuries.

Question 3: INTERMEDIATE

A hospital pharmacist discovers that a nursing unit has been using conventional (non-safety) hypodermic needles for insulin administration because a backorder prevented delivery of the usual safety-engineered devices. The pharmacist-in-charge approved continuing with conventional needles during the shortage. Upon OSHA inspection, what violation(s), if any, could be cited, and what should the pharmacist have done differently?
Show answer
Under the revised OSHA Bloodborne Pathogens Standard (incorporating the Needlestick Safety and Prevention Act), employers must use safety-engineered sharps devices wherever commercially available. A supply chain disruption does not automatically exempt the employer from this requirement. The pharmacist-in-charge should have sourced alternative SESDs from secondary distributors, arranged emergency procurement from another manufacturer's equivalent product, or documented exhaustive efforts to obtain safety devices while implementing enhanced work practice controls (e.g., single-handed scoop technique training refresher, additional sharps containers). The employer could face a citation for failure to implement engineering controls if alternative safety devices were available on the market. Proper documentation of the shortage and good-faith procurement efforts would be a mitigating factor during an investigation.

Question 4: APPLIED

A 67-year-old patient with type 2 diabetes presents to your community pharmacy for a medication therapy management session. The patient reports disposing of used insulin pen needles by capping them and throwing them directly into the household trash. The patient lives in a state that prohibits sharps disposal in household waste. What counseling points should the pharmacist provide, and what disposal options should be recommended?
Show answer
The pharmacist should first explain the safety risks of disposing sharps in household trash: sanitation workers, household members, and community members can sustain needlestick injuries from improperly discarded sharps. The pharmacist should recommend the following options: (1) Purchase an FDA-cleared home sharps disposal container—available at most pharmacies—and bring the sealed container to a household hazardous waste collection event or participating pharmacy take-back program. (2) Use a sharps mail-back program, where the patient purchases a prepaid container, fills it, and mails it to a licensed destruction facility. (3) Check with the local health department for community sharps drop-off locations. The pharmacist should demonstrate how to properly place the pen needle (without recapping by hand if the safety cap is not built-in) into the container and emphasize replacing the container at three-quarters full. This counseling interaction represents a NAPLEX-testable pharmacist responsibility in patient education and public health protection.

Question 5: CRITICAL THINKING

A hospital pharmacy department is updating its Exposure Control Plan and must decide between two safety-engineered devices for reconstituting hazardous drugs: (A) a closed-system transfer device (CSTD) with an integrated venting mechanism and no exposed needle, or (B) a standard safety needle with a hinged shield designed for general injectable use. Discuss the regulatory, safety, and practical considerations that should inform this decision.
Show answer
This decision involves multiple intersecting regulatory frameworks. USP <800> requires CSTDs for administration of antineoplastic hazardous drugs and strongly recommends them for compounding as well. Device A (CSTD) represents both an engineering control for bloodborne pathogen prevention and a containment strategy for aerosolized drug exposure—addressing the dual hazard of cytotoxic sharps. Device B, while meeting OSHA SESD requirements for general sharps safety, provides no chemical containment and would likely fail to meet USP <800> standards for hazardous drug handling. From a practical standpoint, CSTDs increase per-unit cost but reduce occupational exposure claims, workers' compensation expenses, and regulatory citation risk. The hierarchy of controls also favors Device A because the CSTD eliminates the needle hazard entirely (needleless design) while Device B merely shields it (active safety mechanism). The pharmacy department should select Device A and document the evaluation process—including frontline worker input—in the annual Exposure Control Plan review, satisfying both OSHA and USP <800> requirements simultaneously.

SUMMARY

Sharps Handling — Key Concepts Review

Summary

Safe sharps handling is governed by a hierarchy of controls that prioritizes elimination (needleless systems) and engineering controls (safety-engineered sharps devices, sharps containers) over work practice controls (one-handed scoop technique, neutral zone passing) and PPE. The OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030), as amended by the Needlestick Safety and Prevention Act, mandates employer-developed Exposure Control Plans, annual review with frontline worker input, use of commercially available SESDs, sharps injury logging, and employee training.

Following a needlestick injury, the pharmacist must immediately wash the site, report and document the incident, determine the source patient's serologic status, evaluate the need for post-exposure prophylaxis (HIV PEP within 1–2 hours; HBIG/vaccine for HBV; no PEP for HCV), and undergo follow-up serology. For hazardous drug sharps, USP <800> imposes additional requirements including closed-system transfer devices, chemotherapy-rated disposal containers, and enhanced PPE. Pharmacists also serve a vital role in patient education on safe home sharps disposal using FDA-cleared containers, mail-back programs, and community collection sites.

Varsity Tutors • NAPLEX • Sharps Handling